Jeffrey B. Mirviss Sells 4,675 Shares of Boston Scientific Co. (NYSE:BSX) Stock

Boston Scientific Co. (NYSE:BSX) EVP Jeffrey B. Mirviss sold 4,675 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $104.25, for a total transaction of $487,368.75. Following the transaction, the executive vice president now directly owns 28,454 shares in the company, valued at approximately $2,966,329.50. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Boston Scientific Price Performance

Shares of BSX stock opened at $101.61 on Thursday. The firm has a market capitalization of $149.96 billion, a price-to-earnings ratio of 81.29, a PEG ratio of 2.79 and a beta of 0.80. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The stock’s 50-day simple moving average is $98.73 and its 200-day simple moving average is $89.95. Boston Scientific Co. has a fifty-two week low of $65.52 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, equities analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Wells Fargo & Company lifted their target price on Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Morgan Stanley lifted their price objective on Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Canaccord Genuity Group increased their target price on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Citigroup boosted their price target on shares of Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Finally, JPMorgan Chase & Co. upped their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Two analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $107.39.

Hedge Funds Weigh In On Boston Scientific

Several hedge funds have recently made changes to their positions in the company. Private Advisor Group LLC increased its holdings in shares of Boston Scientific by 2.7% in the third quarter. Private Advisor Group LLC now owns 36,003 shares of the medical equipment provider’s stock valued at $3,017,000 after purchasing an additional 944 shares during the period. PFG Investments LLC increased its holdings in Boston Scientific by 3.3% in the 3rd quarter. PFG Investments LLC now owns 7,988 shares of the medical equipment provider’s stock worth $669,000 after buying an additional 258 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in Boston Scientific by 123.1% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 158,538 shares of the medical equipment provider’s stock worth $13,285,000 after buying an additional 87,470 shares during the last quarter. Cavalier Investments LLC lifted its stake in Boston Scientific by 6.7% during the 3rd quarter. Cavalier Investments LLC now owns 71,841 shares of the medical equipment provider’s stock valued at $6,020,000 after acquiring an additional 4,485 shares during the period. Finally, Patriot Financial Group Insurance Agency LLC boosted its holdings in shares of Boston Scientific by 11.8% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 13,718 shares of the medical equipment provider’s stock valued at $1,150,000 after acquiring an additional 1,445 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.